cms.bioaccessla.com

Clinical trial insurance for medical device studies in Latin America

Written by

Julio Martinez-Clark

in

,

Sponsors still ask the same question before every Latin American device study start: what clinical trial insurance do we need for ethics, import, and a second country? The answer is a country-snapshot checklist — territory, named insureds, language, runoff — not a hallway promise that “we’re global.”

I am Julio Martinez-Clark, CEO of bioaccess®. This hub is the missing checklist page that satellite posts already pointed at. It is general information, not insurance, legal, or regulatory advice. Confirm current ethics, import, and coverage rules with qualified advisers and a licensed broker. We do not invent premiums, limits, or carrier rates here. We do not claim a named carrier as a signed bioaccess® partner on this page. No patient data. No unpublished client. Always bioaccess®.

The CRO is not the carrier

Founders type “buy clinical trial insurance” and land on CROs, brokers, and hospital MSAs in the same result set. Those are three jobs:

  • Carrier. Underwrites participant injury, medical expenses for trial-related events, defense, and site/investigator indemnification — if the form matches the protocol. A hallway conversation is not a binder.
  • Broker. Places the form, translations, additional-insured endorsements, and territory wording. Licensed where the paper has to sit.
  • CRO. Protocol, IB, ICF, ethics and national-authority packet, investigational importer, ISO 14155 monitoring, SAE clock, TMF, and the 21 CFR 812.28 narrative. Eligibility of foreign data is not FDA clearance.

Mixing those jobs is how a startup buys a U.S. product-liability rider, emails an English PDF to an ethics committee, and gets a resubmission. Product liability is not clinical-trial liability. A site’s institutional policy is not the sponsor’s trial form.

The country-snapshot checklist

Insurance documentation usually sits in the ethics / national-authority packet, not as a post-approval formality. Before first submission, write five lines and make the certificate match them:

  1. Territory. Name every country on the protocol. A Delaware HoldCo certificate that never names Panama, El Salvador, Chile, or Brazil is decoration.
  2. Named insureds. Sponsor entity legal name as it appears on the CTA and ICF. Add site and principal investigator as additional insureds when the committee requires it.
  3. Language. Spanish for Spanish-speaking committees; Portuguese for CEP/CONEP in Brazil. An English-only certificate is a classic resubmission. See Spanish or Portuguese insurance certificates for LATAM ethics.
  4. Period and runoff. Policy period through last-patient last-visit plus the protocol follow-up window. Confirm claims-made vs occurrence and any runoff the committee or CTA expects. Do not invent a pan-regional day count here.
  5. Claims-notice language. Must sit next to the SAE clock, not against it. The person who opens the SAE notice should know who opens the claims notice.

We will not invent a per-participant dollar limit on this page. Individual ethics committees set thresholds. Ask the carrier and the CRO together before the packet goes in.

Local admitted paper vs controlled master

Two workable patterns — confirm which the reviewing body will stamp:

  • Local admitted policy in the study country, with certificates that name the site and PI.
  • Controlled master that can issue local certificates (or notarized Spanish/Portuguese summaries) for each country on the protocol.

A “controlled master” that never issues a local certificate is a slide, not a submission. A local-only policy that cannot travel to a second Latin American country is a one-country trap. When country 2 sits, the move is an endorsement or a new certificate — not a new CRO contract that pretends to be a binder. That intercept lives on adding a second LATAM country endorsement.

Country snapshots (use live hubs; confirm on filing day)

These are operator snapshots for insurance timing, not rate cards:

  • Panama (MINSA / CNBI). Ethics review through institutional bioethics committees registered with CNBI. Published ethics typically 3–5 weeks on the Panama hub; insurance exhibits belong in that packet. Per-patient cost bands already published there: about USD 12,000–22,000. Spanish certificate language is the usual ask.
  • El Salvador (SRS / CNEIS). Parallel SRS and CNEIS review; country hub publishes a 30–60 day startup band. Financial responsibility for participant injury still belongs in the ethics packet before initiation. Keep trial insurance off the commercial registro track.
  • Chile (ISP). Fast-corridor country with efficient ethics + ISP pathways. Plan Spanish certificates and additional insureds before the ethics date, same as the rest of the corridor.
  • Costa Rica. Corridor speed with concentrated sites. Same five-line checklist as above.
  • Brazil (ANVISA / CEP). Portuguese certificate of insurance is not optional stationery for CEP/CONEP. Use the Brazil clinical-trials hub for clocks — do not invent medians here.
  • Mexico (COFEPRIS). Keep trial liability separate from registro sanitario. Territory must name Mexico before the ethics packet goes in.
  • Colombia (INVIMA). Public line unchanged: bioaccess® still runs clinical trials in Colombia and owns CRO-in-Colombia; INVIMA commercial registration remains. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. A Bogotá ethics packet still wants financial responsibility for participant injury — that does not flip the FIH recommendation line.

What bioaccess® owns after you have a quote

  • Regulatory-fit geography — not country tourism.
  • Protocol, IB, ICF, and the ethics / national-authority packet with insurance documents in the same stack — not a parallel founder email.
  • Importer of record and device accountability. A binder does not import the investigational product.
  • Site activation: contracts, training, investigational product, EDC, monitoring plan. A site MSA that “includes insurance” is still not ISO 14155 monitoring.
  • Introducing a specialty carrier when the founder does not already have admitted paper. Introduction is not a signed partnership on this page. We do not invent rates.

The firm was founded in 2010. Public device case studies already on site (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™) show FIH execution with import and insurance as workstreams — not as bioaccess® underwriting. Public copy mentioning a $10M Sangria™ trial policy describes CRO coordination, not a SKU or rate we invent here.

Common failures that stall ethics

  • English-only certificate in a Spanish or Portuguese committee folder.
  • Territory that lists “worldwide” but never names the study country.
  • Product-liability or general-liability rider treated as trial liability.
  • Site MSA “insurance included” with no sponsor trial form.
  • Country 2 added to the protocol with no endorsement calendar.
  • Policy period that ends before last-patient last-visit plus follow-up.

Related reading

Need the insurance exhibit sequenced with your LATAM FIH packet? bioaccess® runs the trial under ISO 14155 and can introduce a specialty carrier. We do not underwrite. Contact Julio Martinez-Clark, Co-Founder & CEO, at jmclark@bioaccessla.com or +1 (954) 903-7210.

Frequently asked questions

Does bioaccess® sell clinical trial insurance?

No. We are the First-in-Human CRO. We can introduce a carrier. We do not underwrite. We do not bind. We do not invent a rate card on this page.

What should a LATAM clinical trial insurance certificate show?

Territory naming every study country, correct named insureds (and additional insureds when required), Spanish or Portuguese language when the committee asks, policy period through LPLV plus follow-up / runoff as required, and claims-notice language that can sit next to the SAE clock.

Is this the same article as the Spanish/Portuguese certificate page?

No. That page is the language intercept for the clerk who stamps the exhibit. This hub is the country-snapshot checklist (territory, named insureds, language, runoff). The second-country page is the endorsement intercept. Distinct slugs. Same rule: the CRO runs the trial; a carrier writes the paper.

Can a U.S. product-liability policy cover a LATAM device FIH?

Only if the territory clause and the trial-liability form actually name the countries and the investigational activity. Many U.S. GL/PL policies exclude OUS research. Get it in writing from the carrier. A verbal “we’re global” is not an ethics exhibit.

When do we add insurance for a second LATAM country?

Before the second ethics packet goes in. Ask whether the master can certificate the new country; if not, start local admitted paper in time for that ethics date. See the endorsement page.

More posts